The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: Protocol for a Systematic Review.
Open accessAbstract
Background/Objectives: Fibrates reduce cardiovascular risk in the general population and in patients with chronic kidney disease (CKD). Although, they are commonly used as second-line agents in addition to statins for hypertriglyceridemia, their use in CKD is limited due to a decrease of glomerular filtration rate (GFR) at treatment initiation. This change in GFR is reversible with fibrate discontinuation. Importantly, randomised control trials with fibrate treatment have demonstrated reduction in proteinuria and benefit for microvascular diabetic complications. In addition, a number of experimental studies have shown nephroprotective effects with fibrates through attenuation of renal fibrosis and inflammation. Thus, the effect of fibrates on renal outcomes remains undetermined. The objective of this systematic review is to summarize the evidence from randomised controlled studies and provide pooled estimates on the effect of fibrates on short- and long-term renal outcomes. Methods/Design: The study will be contacted according to the Cochrane Collaboration principles for Systematic reviews. We will include randomised trials comparing fibrate to placebo or studies comparing the addition of fibrate on statin versus statin alone and reporting on the short- and long-term effects on renal function, CKD progression and proteinuria. We will examine studies including patients with established CKD and those studies including patients at risk of developing CKD, separately. A comprehensive summary of the evidence will be reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Data from included studies suitable for metanalysis will be analyses accordingly to provide quantitative estimates using a random effects model. The Cochrane Collaboration tool for assessing the risk of bias in randomized clinical trials will be utilised. The quality of the evidence from included studies will be addressed descriptively using GRADE (Grading of Recommendations, Assessment, Development and Evaluations).Discussion: The results of this systematic review will be informative for clinicians. A summary of high-level evidence with robust estimates of the effect of fibrates on safety and renal outcomes may be used to inform clinical practice guideline development for dyslipidaemias and primary and secondary prevention of CVD. Systematic review registration: PROSPERO CRD42020187764
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A predefined protocol was registered in PROSPERO with registration number CRD42020187764.
“A predefined protocol was drafted and registered in the Prospective Register of Systematic Reviews (PROSPERO) with registration number CRD42020187764; it can also be found as a publication in a pre-prints platform [12].”
From The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies (2022) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · see citing works
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524 · see citing works
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575 · see citing works
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607 · see citing works
Utilization of the PICO framework to improve searching PubMed for clinical questions
Schardt, C., Adams, M. B., Owens, T., Keitz, S., & Fontelo, P. (2007) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-7-16 · Cited by 3,053 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479 · see citing works
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213 · see citing works
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1× · see citing works
“73m2 [5] patients with major risk factors for developing CKD or proteinuria; hypertension, diabetes, dyslipidaemias, obesity, cardiovascular disease (heart failure, stroke, ischemic heart disease, coronary revascularization).”
BackgroundFoley, R. N., Murray, A. M., Li, S., Herzog, C. A., McBean, A. M., Eggers, P. W., & Collins, A. J. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004030203 · Cited by 967 · see citing works
PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts
Beller, E. M., Glasziou, P. P., Altman, D. G., Hopewell, S., Bastian, H., Chalmers, I., Gøtzsche, P. C., Lasserson, T., Tovey, D., & for the PRISMA for Abstracts Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001419 · Cited by 706 · see citing works
Mahmoodi, B. K., Matsushita, K., Woodward, M., Blankestijn, P. J., Círillo, M., Ohkubo, T., Rossing, P. R., Sarnak, M. J., Stengel, B., Yamagishi, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61272-0 · Cited by 454 · see citing works
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · see citing works
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338 · see citing works
Atherosclerosis in Chronic Kidney Disease
Valdivielso, J. M., Rodrı́guez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortíz, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 311 · see citing works
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Park, C. W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M.-T., Fan, X., Davis, L., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000209 · Cited by 202 · see citing works
McClellan, W. M., Langston, R. D., & Presley, R. J. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000129982.10611.4c · Cited by 135 · see citing works
Dumaine, R. L., Collet, J., Tanguy, M., Mansencal, N., Dubois‐Randé, J., Henry, P., Steg, P. G., Michel, P.-L., Allouch, P., Cohen, A. A., et al. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.035 · Cited by 58 · see citing works
Chronic Kidney Disease, Plasma Lipoproteins, and Coronary Artery Calcium Incidence
Lamprea-Montealegre, J. A., McClelland, R. L., Astor, B. C., Matsushita, K., Shlipak, M. G., de Boer, I. H., & Szklo, M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300624 · Cited by 43 · see citing works
CKD, Plasma Lipids, and Common Carotid Intima-Media Thickness
Lamprea-Montealegre, J. A., Astor, B. C., McClelland, R. L., de Boer, I. H., Burke, G. L., Sibley, C. T., O’Leary, D. H., Sharrett, A. R., & Szklo, M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02090212 · Cited by 34 · see citing works
Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease
Lamprea-Montealegre, J. A., McClelland, R. L., Grams, M. E., Ouyang, P., Szklo, M., & de Boer, I. H. (2018) · Heart · doi:10.1136/heartjnl-2017-312794 · Cited by 32 · see citing works
Nicolaou, O., Kousios, A., Sokratous, K., Potamiti, L., Koniali, L., Neophytou, G., Papacharalampous, R., Zanti, M., Ioannou, K. I., Hadjisavvas, A., et al. (2020) · Nephrology · doi:10.1111/nep.13764 · Cited by 5 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Hadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46 · see citing works
Self-citation
- Authors
- Kousios, A., Hadjivasilis, A., Kouis, P., & Panayiotou, A.
- Affiliations
- Imperial College Healthcare NHS Trust (GB)
- Cyprus University of Technology (CY)
- Medical School, University of Cyprus.
- Cyprus International Institute for Environmental and Public Health, Cyprus Institute of Technology
- Corresponding author
- Kousios, Andreas
- Published
- 2020-11-12
- OpenAlex
- W3119694407
- Cited by
- 1
- References
- 24
- Citations by year
- 2022: 1
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Funders
- Cyprus University of Technology
- University of Cyprus
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- fibrates, chronic kidney disease progression, renal function, glomerular filtration rate, proteinuria, renal protection, renal fibrosis, renal inflammation, dyslipidemia, cardiovascular risk, CKD risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
